Two ongoing clinical studies are evaluating the safety and the therapeutic efficacy of allogeneic CD123 CAR-NK cells in R/R AML patients (NCT05574608 and NCTo6201247). The gene discussed is IL3RA; the disease is acute myeloid leukemia.